Your browser doesn't support javascript.
loading
Estatinas: eficacia, seguridad e indicaciones / Statins: useful, security and indications
Maiques Galán, A; Franch Taix, M; Fluixá Carrascosa, C.
Affiliation
  • Maiques Galán, A; Centro de Salud de Manises. España
  • Franch Taix, M; Centro de Salud Bilbao. Bilbao. España
  • Fluixá Carrascosa, C; Consultorio Auxiliar San Antonio de Requena. Valencia. España
Pediátrika (Madr.) ; 25(1): 24-35, ene. 2005. tab
Article in Es | IBECS | ID: ibc-036818
Responsible library: ES1.1
Localization: ES1.1 - BNCS
RESUMEN
Las estatinas han demostrado que son útiles en la prevención de la enfermedad cardiovascular infarto de miocardio, ictus, mortalidad cardiovascular y total. Los beneficios del tratamiento se manifiestan sobre todo en pacientes que han padecido una enfermedad cardiovascular o con un riesgo cardiovascular alto. Las dosis mínimas eficaces de las estatinas en la prevención de la enfermedad cardiovascular son atorvastatina 10 mg/dia, simvastatina 20-40 mg/dia, lovastatina 20-40 mg/dia y pravastatina 40 mg/dia. Estas dosis consiguen un 20% de reducción del cLDL (colesterol de las lipoproteínas de baja densidad) en los ensayos clínicos. La hepatotoxicidad y miotoxicidad son los efectos secundarios más importantes de las estatinas. La elevación de las transaminasas y la aparición de síntomas musculares son la forma de detectarlos. Las estatinas están indicadas para el tratamiento de la enfermedad cardiovascular o en un paciente con riesgo cardiovascular alto cuando el cLDL sea superior a 115 mg/dl
ABSTRACT
The statins have demonstrated that they are useful in the prevention of the cardiovascular illness myocardial infarction, stroke, cardiovascular and total mortality. The benefits of the treatment are manifested mainly in patients that have suffered a cardiovascular illness or with a high cardiovascular risk. The effective minimum dose daily of the statins in the prevention of the cardiovascular illness is atorvastatin 10 mg, simvastatin 20-40 mg, lovastatin 20- 40 mg and pravastatin 40 mg. These doses get 20% of reduction of the cLDL (cholesterol of the lipoproteins of low density) in the randomised clinical trials. The hepatic and muscular effects are the most important adverse events. The elevation of the AST or ALT and the appearance of muscular symptoms are the form of detecting them. The treatment with statins is suitable for patients with cardiovascular illness or with high cardiovascular risk when the cLDL is superior to 115 mg/dl
Subject(s)
Search on Google
Collection: National databases / Spain Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Target 3.4: Reduce premature mortality due to noncommunicable diseases / Endocrine System Diseases Database: IBECS Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypercholesterolemia Type of study: Controlled clinical trial / Etiology study / Risk factors Limits: Humans Language: Spanish Journal: Pediátrika (Madr.) Year: 2005 Document type: Article Institution/Affiliation country: Centro de Salud Bilbao/España / Centro de Salud de Manises/España / Consultorio Auxiliar San Antonio de Requena/España
Search on Google
Collection: National databases / Spain Health context: SDG3 - Health and Well-Being / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Target 3.4: Reduce premature mortality due to noncommunicable diseases / Endocrine System Diseases Database: IBECS Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypercholesterolemia Type of study: Controlled clinical trial / Etiology study / Risk factors Limits: Humans Language: Spanish Journal: Pediátrika (Madr.) Year: 2005 Document type: Article Institution/Affiliation country: Centro de Salud Bilbao/España / Centro de Salud de Manises/España / Consultorio Auxiliar San Antonio de Requena/España
...